Skip to content

Nurix Therapeutics, Inc. NRIX Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Nuvation Bio logo
Nuvation BioNUVB
$797K+33.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$1.11M-55.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s unrealized gains on investments?
Nurix Therapeutics, Inc. (NRIX) reported unrealized gains on investments of $88K in Q4 2025.
What does unrealized gains on investments mean?
This represents the cumulative positive change in the fair value of available-for-sale investment securities compared to their original cost basis. It reflects potential gains that have not yet been realized through the sale of the assets. For a biopharmaceutical company, this indicates the performance of the treasury portfolio and the unrealized appreciation of liquid assets.